Complete Conference Coverage Archive

CDX-011 Does Not Benefit Patients With Osteosarcoma

CDX-011 Does Not Benefit Patients With Osteosarcoma

No significant association between GPNBM levels and disease response was found. Due to futility, the researchers did not pursue a second stage of the trial.

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

Researchers are evaluating whether BLU-285, which is active regardless of resistance-associated mutations, is safe and effective among patients with an imatinib-resistant GIST.

Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

In a randomized phase 2 trial, CASPS, researchers enrolled 48 patients with metastatic ASPS that progressed within the preceding 6 months. The primary endpoint was change in tumor size.

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2

Although endocrine therapy has been the standard of care for HR+/HER2- breast cancer, cyclin-D and cyclin-dependent kinase (CDK) dysregulation-driven resistance to this treatment occurs at very high rates among patients.

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

Trabectedin, an alkylating agent, removes tumor growth-promoting M2 macrophages, leading to more effective natural killer T cell activity.

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

For an ongoing phase 2 trial, researchers are recruiting 30 patients with advanced or metastatic sarcoma to receive the drug combination.

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

In an ongoing phase 2 study, researchers are evaluating the safety and efficacy of a 5-day hypofractionated radiotherapy course.

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Researchers reported outcomes for patients who underwent a second resection after disease recurrence.

National Cancer Database May Underestimate the Burden of Sarcomas

National Cancer Database May Underestimate the Burden of Sarcomas

Institutional policies determine whether cancers are coded by disease type or organ site, which can lead to miscalculations of the global burden of a particular cancer type.

First-line Osimertinib for EGFR-mutation Positive NSCLC

First-line Osimertinib for EGFR-mutation Positive NSCLC

The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer

Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL

In order to optimize therapeutic sequencing among patients with CLL, 5 patient aspects must be considered.

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials

In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma

Four recently approved treatment regimens have demonstrated a PFS benefit for patients with RRMM relative to Rd, but no head-to-head studies have been conducted.

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator's choice chemotherapy.

Lung Cancer Treatment in North America: Recent Advances and Future Promises

Lung Cancer Treatment in North America: Recent Advances and Future Promises

At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and are refractory to EGFR TKIs; there are no targeted therapies available for this patient population.

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients, of whom 6 were T790M-positive and 5 were T790M-negative.

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Investigators randomly assigned 95 patients with ED-SCLC to receive pazopanib 800 mg daily or placebo.

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/carboplatin alone.

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

Researchers analyzed the resistance biopsies and plasma specimens of 119 patients with T790M-positive NSCLC treated with osimertinib.

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

Researchers enrolled 248 patients who progressed on pemetrexed-based chemotherapy with or without bevacizumab to receive second-line anetumab ravtansine or vinorelbine.

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

Researchers randomly assigned 89 patients with NSCLC to the SLND arm, in which patients underwent standard lung resection with SLND, or to the BML arm, in which patients received SLND plus contralateral mediastinal lymphadenectomy.

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs among patients treated with chemotherapy plus RT or chemotherapy alone.

SABR Improves Overall Survival Compared With CRT in NSCLC

SABR Improves Overall Survival Compared With CRT in NSCLC

The purpose of this study was to compare the effectiveness of SABR with CRT in prolonging time to local failure in this patient population.

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine.

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

Although there was less toxicity, neoadjuvant letrozole plus palbociclib had similar response and BCS rates when compared with chemotherapy.

BRCA2 Mutations Associated With Poor Outcomes in mCRPC

BRCA2 Mutations Associated With Poor Outcomes in mCRPC

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

This trial sought to determine if the letrozole and taselisib combination was effective in early-stage breast cancer.

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.

Sarcoma Resection at Expert Centers Associated With Better Outcomes

Sarcoma Resection at Expert Centers Associated With Better Outcomes

Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive cellular immunotherapy has not been widely used for cancer treatment.

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.

Engagement Is Survival: My Take on ASCO 2017

Engagement Is Survival: My Take on ASCO 2017

Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Data from the BFORE study showed significantly higher 12-month major molecular remission and complete cytogenetic response with bosutinib.

Momelotinib for Previously Treated Patients With Myelofibrosis

Momelotinib for Previously Treated Patients With Myelofibrosis

For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.

Dabrafenib Plus Trametinib Promising in Melanoma

Dabrafenib Plus Trametinib Promising in Melanoma

Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.

Establishing a Short-term Response Endpoint for mCRPC Trials

Establishing a Short-term Response Endpoint for mCRPC Trials

After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.

Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer

Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer

When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters